Special Issue

The Current State of Psychiatry: Personalized Medicine and Treatment

Message from the Guest Editors

Psychiatric disorders have a high prevalence and the significant burden they impose on patients and society. The lack of reliable and valid biomarkers for Psychiatric disorders has long limited the usefulness of psychiatric clinical research, and patients still suffer from various psychiatric disorders that cannot be objectively diagnosed. Beyond group comparison studies, research aimed at personalized medicine is still challenging but promising for the better prevention and treatment of patients with psychiatric disorders. This Special Issue aims at improving prevention, diagnosis, intervention, treatment, and other aspects of psychiatry from the standpoint of personalized medicine. Research areas include but are not limited to:

- neurophysiology studies on psychiatry;
- neuroimaging studies on psychiatry;
- genetic studies on psychiatry;
- other personalized biomarkers for psychiatry;
- neuropsychopharmacology studies;
- neuromodulation treatments for psychiatry;
- psychological treatments;
- preventions and early interventions for psychiatry;
- neuropsychology and cognitive psychiatry.

Guest Editors

Dr. Daichi Sone

Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan

Dr. Yoshihiro Noda

Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

Deadline for manuscript submissions

closed (5 August 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/109623

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

